LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

MannKind Corp

Fechado

SetorSaúde

5.39 0.37

Visão Geral

Variação de preço das ações

24h

Atual

Mín

5.37

Máximo

5.54

Indicadores-chave

By Trading Economics

Rendimento

-12M

668K

Vendas

-1.8M

77M

P/E

Médio do Setor

48.909

35.293

Margem de lucro

0.873

Funcionários

403

EBITDA

-17M

9.7M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+91.62% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

518M

1.7B

Abertura anterior

5.02

Fecho anterior

5.39

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

MannKind Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de set. de 2025, 23:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 de set. de 2025, 22:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 de set. de 2025, 21:59 UTC

Ganhos

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 de set. de 2025, 23:44 UTC

Conversa de Mercado

Nikkei May Rise as Yen Weakens -- Market Talk

17 de set. de 2025, 23:39 UTC

Conversa de Mercado

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 de set. de 2025, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 de set. de 2025, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 de set. de 2025, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 de set. de 2025, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 de set. de 2025, 22:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 de set. de 2025, 21:00 UTC

Ganhos

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 de set. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

17 de set. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

17 de set. de 2025, 19:59 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de set. de 2025, 19:59 UTC

Conversa de Mercado

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 de set. de 2025, 19:07 UTC

Conversa de Mercado

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 de set. de 2025, 18:43 UTC

Conversa de Mercado

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 de set. de 2025, 18:38 UTC

Conversa de Mercado

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 de set. de 2025, 18:20 UTC

Conversa de Mercado

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 de set. de 2025, 18:18 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de set. de 2025, 18:18 UTC

Conversa de Mercado

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 de set. de 2025, 18:14 UTC

Conversa de Mercado

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 de set. de 2025, 17:59 UTC

Conversa de Mercado

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 de set. de 2025, 17:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 de set. de 2025, 17:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 de set. de 2025, 16:51 UTC

Ganhos

Correct: Exor 1H Net Loss -EUR624M

17 de set. de 2025, 16:34 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de set. de 2025, 16:34 UTC

Conversa de Mercado

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 de set. de 2025, 16:25 UTC

Ganhos

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 de set. de 2025, 16:23 UTC

Ganhos

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Comparação entre Pares

Variação de preço

MannKind Corp Previsão

Preço-alvo

By TipRanks

91.62% parte superior

Previsão para 12 meses

Média 10.29 USD  91.62%

Máximo 15 USD

Mínimo 7 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para MannKind Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

7 ratings

7

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

4.079 / 4.323Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
help-icon Live chat